The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Trial reports a 15% difference in high PrEP adherence among participants who received vouchers compared to those who didn’t – but this fell significantly after the vouchers stopped.
Ring containing the antiretroviral drug dapivirine could be available in Africa as early as 2021 after it was found to reduce women’s HIV risk by 30 to 50%.
Modelling finds PrEP has the potential to avert between 3 and 8% of HIV infections in 13 African and Caribbean countries by 2030 if three key populations can access it
Research on PrEP safety for pregnant women and their babies finds no adverse effects – but knowledge gaps remain.
The largest-ever study examining the effectiveness of condoms for anal sex finds remarkably low levels of failure, and calls to label their use in this way.
Findings from France and Canada suggest it is safe to offer men who have sex with men a choice between daily and ‘on-demand’ PrEP if they are not having frequent sex.
To what extent do existing policies relating to age of consent for sexual reproductive health (SRH) services also affect PrEP access?
New technical guidance from the World Health Organization recognises effectiveness of event-driven PrEP for gay men following Prevenir study results.
New study finds treatment adherence a major challenge for excluded and hard to reach populations living with HIV, exacerbating existing health inequalities.
PARTNER2 trial results confirm that gay men can also benefit from U=U (undetectable=untransmittable), as Lancet publishes final study report.
